SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Cannabis > Veritas Pharma, Inc. (VRTHF)

Corporate Update from Veritas Pharma ~ June 27, 2016

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
zigzagman Member Profile
Member Level 
Followed By 529
Posts 97,434
Boards Moderated 6
Alias Born 05/19/07
160x600 placeholder
zigzagman Member Level  Monday, 06/27/16 11:40:48 AM
Re: None
Post # of 37 
Corporate Update from Veritas Pharma ~ June 27, 2016

Vancouver, B.C. – Veritas Pharma, Inc. (“VRT” or the “Company”) (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP) is pleased to announce a Corporate Update.

http://veritaspharmainc.com/2016/06/27/investor-news-veritas-pharma

Corporate Update

During the first two quarters of 2016, Veritas Pharma has managed to reach significant milestones in achieving its goals. These milestones include formation of a uniquely qualified Board of Directors, completion of Private Placement, as well as initiating the important research and progressing towards identifying potentially new therapeutic strains of cannabis.

On April 19th, 2016, Veritas Pharma’s Board of Directors was strengthened by the appointment of Dr. Donald R. Carlow. He was the former president and CEO of the British Columbia Cancer Agency as well as principal administrator of various other cancer organizations in Canada. Dr. Carlow provides substantial experience and could deliver clinical insight into development of Veritas’ new strains for treatment of cancer pain and chemotherapy induced emesis. His appointment was an addition to an already versatile Board with significant experience in finance, pharmacology, and agriculture.

Veritas Pharma, through two tranches of non-brokered private placement, accumulated aggregate gross proceeds of $1,116,000. The Company is investing these funds in Cannevert Therapeutics Ltd., a Vancouver, BC company made up of academics at The University of British Columbia. Their goal is to discover new Cannabis strains for specific disease conditions. Cannevert is also attempting to match much of this money with the help of academic-industry grants as well as scientific tax credits.

On May 3rd Veritas announced that Cannevert Therapeutics received a Health Canada exemption to legally purchase cannabis from a designated supplier for research purposes. This was a significant event for Cannevert in that it could now fully conduct chemical and pharmacological screening assays to determine the therapeutic potential of a variety of cannabis cultivars. Concurrent with R&D efforts, Veritas Pharma in conjunction with Cannevert Therapeutics are attempting to protect potential candidate strains through the filing of patent applications and acquiring plant breeder’s rights. Veritas CEO Lui Franciosi commented, “We are extremely excited now to see that, with Health Canada exemption and arrival of initial group of cannabis strains, our work has begun. We believe Veritas’ progress is well within our initial set timeline.”

Once the pharmacological tests are completed, the next step is to take the cannabis strains with the best therapeutic potential and proceed to human clinical trials. This step would firmly establish the clinical utility of each cultivar compared to standard medical treatment. Success of these clinical trials will provide doctors and patients with scientific evidence to recommend and use Veritas proprietary medical marijuana strains with confidence.

Industry Overview

Medical cannabis industry is one of the most exciting segments of pharmaceutical industry. Bank of America estimated this industry within US to stands at $2.9 billion, and projected to grow between $10.8 to $35 billion in five years.

This projected growth is due to several driving factors. Increasing positive publicity as well as continued legalization trends nationally and at individual state levels within US. For example, the newly elected Canadian Prime Minister Justin Trudeau has promised complete legalization of cannabis for recreational use as part of his election platform. Crucially, one of the main drivers has simply been the emerging research highlighting the medical benefits of cannabis. The emerging medicinal versatility of cannabis is quiet vast, ranging from pain management to epilepsy.

“It doesn’t have a high potential for abuse, and there are very legitimate medical applications. In fact, sometimes marijuana is the only thing that works. We have been terribly and systematically misled for over nearly 70 years in the United States, and I apologize for my own role in that.” commented Dr. Sanja Gupda, CNN’s Chief Medical Correspondent and Neurosurgeon

Industry Approach

The two approaches in unlocking the medical benefits of cannabis thus far have been the use of the traditional “big pharma” approach in which the cannabis is broken down to its individual constituents, i.e., molecules and then each tested separately for their safety and effectiveness in various patient populations; or alternatively, the ‘holistic’ approach in which the medical marijuana growers simply prescribe the whole plant for specific ailments without any scientific evidence to based their claims of clinical utility.

Veritas Pharma’s Approach

Veritas Pharma uses elements of both approaches noted above. It is amongst the first in Canada to scientifically investigate the claims made about the therapeutic benefits of the whole cannabis plant. Veritas’ mission is to discover and develop new proprietary strains for specific disease conditions and to provide patients and physicians with the necessary scientific evidence to use medical marijuana with confidence.
Veritas has developed a three-pronged approach to research and development:

First, we aim to chemically profile different marijuana cultivars.

Subsequently, those same cultivars will pharmacologically be profiled in the search for disease-specific strains.

Finally, we aim to perform clinical trials to establish the clinical utility of each cultivar administrated as a dried leaf or an oil extract.

This unique approach has the advantage of being low cost, and allows for faster market entry, providing doctors and patients with conclusive scientific evidence to recommend and use medical marijuana with confidence. This “lean and mean” approach has already gained attention within investment media. Additionally, the presence of such evidence could potentially develop the platform allowing coverage through medical insurance providers.

Veritas Pharma CEO, Dr. Lui Franciosi, explains that Veritas has “the skillset and the abilities to potentially substantiate claims surrounding marijuana for medicinal use. Not only from a scientific, but an intellectual property point of view, protecting our research and discovery in this exciting space.”

The Scientific Team

To achieve above goals, Veritas Pharma is investing in Cannevert Therapeutics, which consists of a team of chemists, pharmacologists and anesthetists with a successful track record of drug discovery and development. Veritas CEO Dr. Franciosi commented, “Investing in Cannevert will enable Veritas to be at the forefront of this evolving industry. These scientists have the rare skills necessary to discover new medicines, with a history of generating over $1 billion worth of investor value. They will likely repeat their success again, this time through development of new and unique strains of medical cannabis for a variety of unmet medical needs.”

Prof. Michael Walker is the President and Head of Biology for Cannevert Therapeutics. His impressive drug discovery track record extends to several successful companies, including Cardiome Pharma (TSX:COM). Verona Pharma PLC (AIM:VRP), and IOmet Pharma UK.

Meet the VRTHF Team ~ https://vimeo.com/169918404/ee7f85183f


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist